STUART DIAMOND - 29 Aug 2022 Form 3 Insider Report for bioAffinity Technologies, Inc. (BIAF)

Role
Director
Signature
/s/ Wilhelm E. Liebmann, as attorney-in-fact for Stuart Diamond
Issuer symbol
BIAF
Transactions as of
29 Aug 2022
Transactions value $
$0
Form type
3
Filing time
02 Dec 2022, 18:08:52 UTC
Next filing
02 Dec 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding BIAF Stock Option (right to buy) 29 Aug 2022 Common Stock 7.14K $4.20 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The number of securities and exercise price reported in this Form 3 reflect the 1-for-7 reverse stock split of the common stock, par value $0.007 (the "Common Stock"), of bioAffinity Technologies, Inc. (the "Issuer"), which became effective with the State of Delaware on June 23, 2022 in connection with the Issuer's initial public offering (the "IPO").
F2 Represents a right to purchase 7,142 shares of Common Stock upon exercise of a ten-year option granted to Mr. Diamond under the Issuer's 2014 Equity Incentive Plan on March 17, 2022. On April 17, 2022, this option began vesting in 12 monthly installments, the first 11 of which are of 595 shares of Common Stock and the last of which is of the remaining 597 shares of Common Stock, subject to Mr. Diamond's continuous service to the Issuer through each vesting date. As of the date of this report, 2,975 shares of Common Stock underlying this option have vested. The remaining unvested shares of Common Stock will vest immediately prior to the closing of the IPO on September 6, 2022.

Remarks:

Exhibit List - Exhibit 24.1: Power of Attorney (Stuart Diamond)